Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Quo vadis, biotech? (Part 2).

J Drews1

  • 1International Biomedicine Management Partners, Basel Switzerland and Managing Partner, Bear Stearns Health Innoventures, New York, NY, USA

Drug Discovery Today
|February 13, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sensing glucose concentrations at GHz frequencies with a fully embedded Biomicro-electromechanical system (BioMEMS).

Journal of applied physics·2014
Same author

Levels of parotid and submandibular/sublingual salivary immunoglobulin A in response to experimental gingivitis in humans.

Clinical oral investigations·2004
Same author

[Mycotic aneurysms--A retrospective analysis].

Zentralblatt fur Chirurgie·2002
Same author

Jürgen Drews discusses the future of the industry. Interviewed by Rebecca N. Lawrence.

Drug discovery today·2001
Same author

Drug discovery: a historical perspective.

Science (New York, N.Y.)·2000
Same author

Research & development. Basic science and pharmaceutical innovation.

Nature biotechnology·1999

Biotechnology company valuations experienced a dramatic shift. Capital availability for biotech initial public offerings and private investments surged unexpectedly, leading to a significant market boom.

Area of Science:

  • Biotechnology
  • Financial Markets
  • Investment Valuation

Background:

  • The biotechnology sector faced capital scarcity towards the end of 1999.
  • Investor confidence and capital availability for biotech firms appeared to be declining.

Purpose of the Study:

  • To analyze the sudden and significant shift in the financial markets concerning biotechnology companies.
  • To understand the "bonanza" experienced by the biotechnology industry.

Main Methods:

  • Market trend analysis.
  • Valuation assessment of biotechnology companies.
  • Review of capital availability for initial public offerings and private investment rounds.

Main Results:

  • A surprising turnaround occurred in the financial markets affecting biotechnology.

Related Experiment Videos

  • The biotechnology industry experienced its largest "bonanza" to date.
  • Capital markets unexpectedly opened for biotech investments.

    • Conclusions:

    • The period demonstrated extreme volatility and a remarkable recovery in biotechnology market valuation.
    • The industry's financial landscape transformed rapidly, defying earlier trends.